Skip to content

Usefulness of homoeopathy in management of essential hypertension.

An open label single arm prospective study to assess the efficacy of Baryta muriaticum in management of Cases of essential hypertension. - NIL

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/067839
Enrollment
30
Registered
2024-05-24
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Baryta muriaticum 30: After enrolment into the study, patient will be prescribed Baryta muriaticum 30 C . Repetition of dosage will be done on the basis of treatment of cases as per the

Sponsors

Dr Nitin Kumar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients diagnosed with essential hypertension from history, examination and routine examination which show no evidence of secondary causes. 2. Patients of age within (25 - 65 years) 3. Both the sexes will be considered. 4. Patients irrespective of their ethnic group, socio economic status and occupation will be considered. 5. Patients who are willing to give their consent for study and comply with regular follow up.

Exclusion criteria

Exclusion criteria: 1. Patients with uncertain diagnosis or patients with routine examinations with suspicion of a secondary cause for hypertension. 2. Patients falling into very high risk group i.e. Stage 3 and 4 hypertension. 3. Patients who are not willing to give their consent for study and not complying with regular follow up. 4. Terminally ill patient, diabetic and conditions affecting function of different organs or systems e.g. hepatic disorders or impaired renal function. 5. Patients on allopathic drugs for hypertension. 6. Pre-existing chronic debilitating illness.

Design outcomes

Primary

MeasureTime frame
Changes from baseline measurements in mean sitting systolic blood pressure and mean sitting diastolic blood pressure. Timepoint: 12 weeks, 24 weeks.

Secondary

MeasureTime frame
Change in the stage of hypertensionTimepoint: 6 weeks, 12 weeks.

Countries

India

Contacts

Public ContactDr Tulika

State National Homoeopathic Medical College And Hospital

drnutansharma@gmail.com8178562292

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026